Myeloproliferative Neoplasms Clinical Trial
Thalidomide in Treating Patients With Myelofibrosis
Summary
Phase II trial to study the effectiveness of thalidomide in treating patients who have myelofibrosis. Thalidomide may stop the growth of myelofibrosis by stopping blood flow to the cancer cells.
Full Description
PRIMARY OBJECTIVES:
I. To investigate whether thalidomide, a potent inhibitor of angiogenic and fibrogenic growth factors, is an effective therapeutic agent in patients with MMM. Specifically, to assess whether thalidomide improves anemia and/or organomegaly in patients with MMM.
II. To assess the effects of thalidomide on the myelofibrotic stroma with respect to microvascular architecture and angiogenesis, collagen and reticulin deposition, and the expression of the mediating growth factors bFGF, TGF-b, and PDGF, and their respective receptors.
OUTLINE: This is a multicenter study.
Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
Patients are followed every 6 months until 5 years from study entry.
Eligibility Criteria
Inclusion Criteria:
Histologically confirmed myelofibrosis with myeloid metaplasia
Agnogenic myeloid metaplasia
Post-polycythemic myeloid metaplasia
Post-thrombocythemic myeloid metaplasia
No metastatic carcinoma, lymphoma, myelodysplasia, hairy cell leukemia, mast cell disease, acute leukemia (including M7), or acute myelofibrosis
No chromosomal translocation t(9;22) or bcr/abl gene rearrangement
Presence of reticulin fibrosis in bone marrow and leukoerythroblastosis and dacrocytosis in peripheral blood
Presence of anemia (hemoglobin less than 10 g/dL), palpable splenomegaly, or hepatomegaly
Performance status - ECOG 0-2
Absolute neutrophil count greater than 750/mm^3
Platelet count less than 400,000/mm^3
WBC less than 50,000/mm^3
Bilirubin no greater than 2 mg/dL (if total bilirubin elevated, direct bilirubin must be normal)
AST no greater than 3 times upper limit of normal (ULN)
Alkaline phosphatase no greater than 3 times ULN
Creatinine no greater than 1.5 mg/dL
Creatinine clearance at least 60 mL/min
Not pregnant or nursing
Negative pregnancy test
Fertile women must use at least 1 highly active method AND 1 additional effective method of contraception for at least 4 weeks before study, during study, and for at least 4 weeks after study
Fertile men must use effective contraception during study and for at least 4 weeks after study
No uncontrolled infection
No concurrent condition that would preclude study
No peripheral neuropathy
At least 1 month since prior interferon, pirfenidone, anagrelide, or epoetin alfa
At least 1 month since prior hydroxyurea or other chemotherapy
At least 1 month since prior corticosteroids or androgen derivatives
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Rochester Minnesota, 55905, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.